Neladalkib: Durable Responses in Pretreated ALK-Positive Lung Cancer

Here are the links extracted from the provided text:

1. https://clinicaltrials.gov/study/NCT05384626 (Clinical trial information)
2. https://investors.nuvalent.com/2025-11-17-Nuvalent-Announces-Positive-Topline-Pivotal-Data-from-ALKOVE-1-Clinical-Trial-of-Neladalkib-for-TKI-Pre-treated-Patients-with-Advanced-ALK-positive-NSCLC ​(Nuvalent press release about⁢ ALKOVE-1 trial data)